HS Linked to Higher Cancer Risk

Investigators report site-specific cancer associations and limited adjusted estimates in meta-analysis.

Category	Detail
Condition	Hidradenitis Suppurativa (HS)
Key Mechanisms	Chronic inflammation and comorbid conditions potentially contributing to increased cancer risk
Target Population	Patients diagnosed with hidradenitis suppurativa
Care Setting	Dermatology and general clinical practice settings

Patients with HS have 1.82 times the odds of developing cancer compared to the general population.
Elevated cancer risks observed for head and neck, respiratory, hematologic, and gastrointestinal cancers.
No significant increased risk found for bone, soft-tissue, breast, CNS, urogenital, or skin cancers including basal-cell carcinoma, squamous-cell carcinoma, and melanoma.

Consider comprehensive cancer risk assessment in patients with HS given elevated odds for multiple cancer types.

Monitor patients with HS for signs of head and neck, respiratory, hematologic, and gastrointestinal malignancies.
Address modifiable risk factors such as smoking and obesity where possible.

Regular clinical surveillance for cancer symptoms in HS patients, especially for lymphoma subtypes and organ-specific cancers with elevated risk.

Increased odds of Hodgkin lymphoma (2.44 times) and non-Hodgkin lymphoma (1.15 times) in unadjusted analyses, though adjusted analyses show variable associations.
Overall cancer risk remains low despite increased odds.

Patients with hidradenitis suppurativa across multiple geographic regions including the US, Europe, and Korea.

Data on disease severity and treatment impact on cancer risk were not available; smoking and obesity data inconsistently reported.

Incorporate cancer risk counseling into HS patient management.
Use a multidisciplinary approach to address inflammation and comorbidities that may contribute to cancer risk.
Apply individualized risk assessment considering patient-specific factors such as smoking status and BMI when available.